Assessment of QTc Interval Prolongation
The most accurate assessment of QTc interval prolongation requires measuring the QT interval from the onset of the QRS complex to the end of the T wave, using the lead with the longest T wave, and applying appropriate heart rate correction formulas based on heart rate. 1
Proper QTc Measurement Technique
Lead Selection
- Select the electrocardiographic lead with the longest, most well-defined T wave 1
- Avoid leads with U waves when possible 1
- Use the same lead for serial measurements in the same patient 1
- If lead change is necessary, clearly document this with the QT measurement 1
Measurement Method
- Measure from the onset of QRS complex to the end of the T wave 1
- For notched or biphasic T waves, use the end of the entire T wave complex 1
- If a U wave is discrete (occurring after T wave returns to baseline), do not include it 1
- If T wave and U wave are superimposed or cannot be separated:
QRS Prolongation Considerations
- If QRS becomes prolonged (e.g., new bundle branch block), either:
- Subtract the increased QRS length from the QT interval, or
- Measure the JT interval (from end of QRS to end of T wave) 1
Heart Rate Correction Methods
Bazett's formula (QTc = QT/√RR):
Fridericia's formula (QTc = QT/∛RR):
Linear regression functions:
Normal and Abnormal QTc Values
| Category | Men | Women |
|---|---|---|
| Normal | ≤450 ms | ≤460 ms |
| Borderline prolonged | 451-480 ms | 461-480 ms |
| Prolonged | >480 ms | >480 ms |
| High-risk prolongation | >500 ms | >500 ms |
| Abnormally short | ≤390 ms | ≤390 ms |
Risk Factors for QTc Prolongation and Torsades de Pointes
Patient-specific factors:
- Female sex
- Older age
- Heart disease (LVH, low LVEF, ischemia)
- Genetic predisposition (family history of syncope, sudden death, LQTS)
- Electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia)
- Metabolic impairment (renal or hepatic failure)
- Bradyarrhythmias 1
Medication-related factors:
ECG Warning Signs of Impending Torsades de Pointes
- Sudden bradycardia or long pauses (e.g., compensatory pauses after ventricular ectopy)
- Enhanced U waves
- T wave alternans
- Nonsustained polymorphic ventricular tachycardia 1
Monitoring Recommendations
- Obtain baseline ECG before starting QT-prolonging medications 3
- For Class III antiarrhythmic drugs, notify prescriber if QTc increases ≥25% from baseline 1
- For drugs like sotalol, discontinue or reduce dose if QTc ≥520 ms 3
- Document QTc in patient's medical record before drug initiation and at least every 8 hours thereafter 1
- Document QTc before and after increases in drug dosage 1
- Use the same recording system and standardized acquisition procedures for serial comparisons 1
Common Pitfalls to Avoid
- Overreliance on Bazett's formula at heart rates outside 60-80 bpm can lead to significant over/under-correction 2
- Inconsistent lead selection introduces unnecessary variability 2
- Difficulty identifying T-wave end, particularly with U waves or bifid T waves 2
- Failing to perform baseline ECG before starting QT-prolonging medications (compliance with recommendations is extremely low, <2% in some studies) 4
- Overlooking QT prolongation in high-risk patients - about 25% of acutely admitted psychiatric patients may have borderline or prolonged QTc intervals 5
- Overinterpreting a single borderline QT measurement without follow-up 2
By following these standardized measurement techniques and monitoring protocols, clinicians can more accurately assess QTc interval prolongation and identify patients at risk for potentially life-threatening arrhythmias.